Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01876719 · ClinicalTrials.gov registry record · Phase 2
AR08 for Treatment of ADHD in Children
A Phase 2 study, sponsored by Arbor Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
NCT01876719 is a Phase 2 study that has completed, run by Arbor Pharmaceuticals. The registered enrollment target is 122 participants.
The verdict
NCT01876719, a Phase 2 study, has completed, sponsored by Arbor Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
Study Summary
This is a multicenter, multiple dose, randomized, double-blind, placebo-controlled, forced titration study. Patients will be randomized to 1 of 4 treatment groups in a 1:1:1:1 ratio. One-hundred twenty (120) patients are planned to be randomized. Each patient will receive AR08 (0.5, 1, or 2 mg per day) or matching placebo for seven (7) weeks.
Interventions
- DRUG Placebo
- DRUG AR08
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01876719
The ClinicalTrials.gov registry entry for NCT01876719 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arbor Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01876719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01876719 about?
NCT01876719 is a clinical study titled "AR08 for Treatment of ADHD in Children". This is a multicenter, multiple dose, randomized, double-blind, placebo-controlled, forced titration study. Patients will be randomized to 1 of 4 treatment groups in a 1:1:1:1 ratio. One-hundred twenty (120) patients are planned to be randomized. Each patient will receive AR08 (0.5, 1, or 2 mg per d...
What is the current status of trial NCT01876719?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2013-06. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01876719?
The interventions under investigation include: Placebo (DRUG), AR08 (DRUG).
Who is sponsoring clinical trial NCT01876719?
This trial is sponsored by Arbor Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.